IART INTEGRA LIFESCIENCES HLDGS C revenue, earnings and financials

For the quarter ended September 30, 2026, INTEGRA LIFESCIENCES HLDGS C reported revenue of $411M (up 2.3% from a year earlier), net income of $14.9M and diluted EPS of $0.19; over the last four quarters revenue was $1.66B and net income $12.7M; for the fiscal year ended December 2025 revenue was $1.64B, up 1.5% on the year before.

IART annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $1.64B, gross profit n/a, operating income −$493M, net income −$517M (margin -31.6%), EPS −$6.74
• Fiscal year ended Dec 2024: revenue $1.61B, gross profit n/a, operating income $28.4M, net income −$6.90M (margin -0.4%), EPS −$0.09
• Fiscal year ended Dec 2023: revenue $1.54B, gross profit n/a, operating income $112M, net income $67.7M (margin 4.4%), EPS $0.84
• Fiscal year ended Dec 2022: revenue $1.56B, gross profit n/a, operating income $239M, net income $181M (margin 11.6%), EPS $2.16
• Fiscal year ended Dec 2021: revenue $1.54B, gross profit n/a, operating income $197M, net income $169M (margin 11.0%), EPS $1.98

IART quarterly revenue and earnings

• Quarter ended Sep 30, 2026: revenue $411M (up 2.3% year over year), net income $14.9M, EPS $0.19
• Quarter ended Jun 30, 2026: revenue $419M (up 0.8% year over year), net income $4.48M, EPS $0.06
• Quarter ended Mar 31, 2026: revenue $392M (up 2.4% year over year), net income −$4.62M, EPS −$0.06
• Quarter ended Dec 31, 2025 (from the annual report): revenue $435M (down 1.7% year over year), net income −$2.03M, EPS −$0.03
• Quarter ended Sep 30, 2025: revenue $402M (up 5.6% year over year), net income −$5.40M, EPS −$0.07
• Quarter ended Jun 30, 2025: revenue $416M (down 0.6% year over year), net income −$484M, EPS −$6.31
• Quarter ended Mar 31, 2025: revenue $383M (up 3.7% year over year), net income −$25.3M, EPS −$0.33
• Quarter ended Dec 31, 2024 (from the annual report): revenue $443M (up 11.5% year over year), net income $19.5M, EPS $0.25
• Quarter ended Sep 30, 2024: revenue $381M (down 0.4% year over year), net income −$10.7M, EPS −$0.14
• Quarter ended Jun 30, 2024: revenue $418M (up 9.7% year over year), net income −$12.4M, EPS −$0.16
• Quarter ended Mar 31, 2024: revenue $369M (down 3.1% year over year), net income −$3.28M, EPS −$0.04
• Quarter ended Dec 31, 2023 (from the annual report): revenue $397M (down 0.2% year over year), net income $19.8M, EPS $0.26
• Quarter ended Sep 30, 2023: revenue $382M (down 0.7% year over year), net income $19.5M, EPS $0.24
• Quarter ended Jun 30, 2023: revenue $381M (down 4.2% year over year), net income $4.18M, EPS $0.05
• Quarter ended Mar 31, 2023: revenue $381M (up 1.1% year over year), net income $24.2M, EPS $0.29
• Quarter ended Dec 31, 2022 (from the annual report): revenue $398M (down 1.8% year over year), net income $53.0M, EPS $0.63
• Quarter ended Sep 30, 2022: revenue $385M (down 0.4% year over year), net income $49.9M, EPS $0.60
• Quarter ended Jun 30, 2022: revenue $398M (up 2.0% year over year), net income $44.8M, EPS $0.54
• Quarter ended Mar 31, 2022: revenue $377M (up 4.6% year over year), net income $32.9M, EPS $0.39
• Quarter ended Dec 31, 2021 (from the annual report): revenue $406M, net income $45.4M, EPS $0.53

IART cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $50.4M, share buybacks $221K
• Fiscal year ended Dec 2024: operating cash flow $129M, share buybacks $52.5M
• Fiscal year ended Dec 2023: operating cash flow $140M, share buybacks $275M
• Fiscal year ended Dec 2022: operating cash flow $264M, share buybacks $125M
• Fiscal year ended Dec 2021: operating cash flow $312M, share buybacks $0

IART balance sheet

• Sep 30, 2026: cash $252M, total assets $3.51B, total liabilities $2.44B, shareholders' equity $1.07B
• Jun 30, 2026: cash $214M, total assets $3.56B, total liabilities $2.52B, shareholders' equity $1.04B
• Mar 31, 2026: cash $237M, total assets $3.58B, total liabilities $2.54B, shareholders' equity $1.04B
• Dec 31, 2025: cash $235M, total assets $3.60B, total liabilities $2.56B, shareholders' equity $1.04B
• Sep 30, 2025: cash $232M, total assets $3.65B, total liabilities $2.61B, shareholders' equity $1.04B
• Jun 30, 2025: cash $218M, total assets $3.67B, total liabilities $2.63B, shareholders' equity $1.04B
• Mar 31, 2025: cash $239M, total assets $4.05B, total liabilities $2.53B, shareholders' equity $1.52B
• Dec 31, 2024: cash $246M, total assets $4.04B, total liabilities $2.49B, shareholders' equity $1.55B

What is IART's revenue?

INTEGRA LIFESCIENCES HLDGS C reported $1.66B of revenue over its last four quarters, through September 30, 2026.

Is IART profitable?

Yes. INTEGRA LIFESCIENCES HLDGS C earned $12.7M over the last four quarters.

What is IART's EPS?

Diluted earnings per share over the last four quarters were $0.16; $0.19 in the latest quarter.

IART ownership and insider trades · All stocks